Novo Nordisk A/S

NVO

NYSE

71.7

USD

+0.97(+1.37%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Novo Nordisk A/S fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

19.43

Price/Book

14.49

Debt/Equity

85.70%

Return on Equity

81.24%

Dividend Yield

2.52%

EBITDA

137.38B

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	126,946,000,000	140,800,000,000	176,954,000,000	232,261,000,000	290,403,000,000
Gross Profit	106,014,000,000	117,142,000,000	148,506,000,000	196,496,000,000	245,881,000,000
Operating Income	54,126,000,000	58,644,000,000	74,809,000,000	102,574,000,000	128,339,000,000
Net Income	42,138,000,000	47,757,000,000	55,525,000,000	83,683,000,000	100,988,000,000
Total Assets	144,922,000,000	194,508,000,000	241,257,000,000	314,486,000,000	465,795,000,000
Total Current Liabilities	70,273,000,000	99,516,000,000	120,940,000,000	169,655,000,000	217,528,000,000
Total Equity	63,325,000,000	70,746,000,000	83,486,000,000	106,561,000,000	143,486,000,000
Free Cash Flow	29,870,000,000	47,615,000,000	64,134,000,000	70,012,000,000	69,659,000,000
Cash from Operations	51,951,000,000	55,000,000,000	78,887,000,000	108,908,000,000	120,968,000,000
Cash from Investing	-22,436,000,000	-31,605,000,000	-24,918,000,000	-43,892,000,000	-128,895,000,000
Cash from Financing	-32,244,000,000	-25,493,000,000	-51,797,000,000	-63,158,000,000	8,735,000,000
Net Change in Cash	-3,185,000,000	-1,507,000,000	1,934,000,000	1,739,000,000	1,263,000,000

Novo Nordisk A/S

NVO

71.7

Novo Nordisk A/S fundamentals

Key ratios

Statements Highlights

Dividends

Analyst Recomendations